Its suboptimal performance, that is, increased levels in benign liver pathologies and teratomas or low levels in small HCC [5], has prompted that US and European guidelines allow HCC surveillance with or without AFP control, in contrast to Asian guidelines that recommend its use in combination with imaging techniques or even other biomarkers [2]. This evidence concerns the gene AFP and hepatocellular carcinoma.